PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71936-2
https://www.valueinhealthjournal.com/article/S1098-3015(11)71936-2/fulltext
Title : PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71936-2&doi=10.1016/S1098-3015(11)71936-2
First page : A258
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 92
Categories :
Tags :
Regions :
ViH Article Tags :